Haldol Depot

Haldol Depot is a depot intramuscular injection containing the active ingredient haloperidol decanoate. It is supplied in a long‑acting formulation designed for intramuscular administration, typically used in the European market. As a typical antipsychotic of the butyrophenone class, Haldol Depot provides sustained dopamine D2 receptor blockade, supporting treatment of chronic psychotic conditions. It is available by prescription only and is administered by a healthcare professional.

Haldol Depot is indicated for several psychiatric indications where long‑acting antipsychotic therapy is appropriate.

- Management of schizophrenia in adults and adolescents. - Treatment of acute psychotic episodes when oral therapy is not feasible. - Maintenance therapy for chronic psychotic disorders to reduce relapse risk. - Adjunctive use in patients with schizoaffective disorder requiring depot medication. - Stabilization of patients with bipolar disorder experiencing severe manic episodes where typical antipsychotics are indicated. - Long‑term control of psychosis in patients with poor medication adherence.

Side effects of Haldol Depot reflect its dopamine antagonism and can vary in frequency and severity.

Common: - Sedation or drowsiness, especially after the initial injection. - Extrapyramidal symptoms such as tremor, muscle rigidity, akathisia, or parkinsonian‑like signs. - Dry mouth, increased salivation, or other anticholinergic‑type effects. - Weight gain, increased appetite, or metabolic changes. - Mild orthostatic dizziness or light‑headedness.

Serious: - Neuroleptic malignant syndrome, presenting with fever, muscle rigidity, autonomic instability, and altered mental status. - Tardive dyskinesia, involving persistent involuntary movements of the face, tongue, or limbs. - Severe hypotension, cardiac arrhythmias, or prolonged QT interval leading to cardiac events. - Elevated prolactin levels causing galactorrhea, menstrual disturbances, or sexual dysfunction.

Before initiating Haldol Depot, clinicians should evaluate several safety considerations and patient‑specific factors.

- Assess history of cardiovascular disease, as the drug may affect blood pressure and cardiac rhythm. - Monitor for signs of extrapyramidal symptoms and tardive dyskinesia, especially with long‑term use. - Evaluate liver and renal function; dose adjustments may be required in severe impairment. - Use caution in patients with a history of seizures, neuroleptic malignant syndrome, or severe dehydration. - Consider pregnancy and lactation status; the medication’s safety profile in these conditions is not well established. - Review any history of hypersensitivity to haloperidol or other butyrophenone agents.

Haldol Depot can interact with other medicines, influencing its efficacy or increasing the risk of adverse effects.

Avoid: - Other dopamine‑blocking agents or high‑potency antipsychotics, which may amplify extrapyramidal toxicity. - Medications that prolong the QT interval, such as certain antiarrhythmics, macrolide antibiotics, or antifungals. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol levels.

Use with caution: - CYP3A4 inducers like carbamazepine or rifampin, which may reduce drug exposure. - CNS depressants, including benzodiazepines or opioids, which can increase sedation. - Anticholinergic agents that may mask extrapyramidal symptoms. - Antihypertensive drugs, as additive hypotensive effects may occur.